Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanhuang Yilong Decoction (SYD) is a traditional Chinese medicine (TCM) herbal formula developed by the General Hospital of Chengdu Military Region (General Hospital of Western Theater Command) for the treatment of active rheumatoid arthritis (RA), particularly in patients presenting with dampness-heat blockage syndrome. The decoction is formulated to clear heat, dispel dampness, and unblock collaterals. Mechanistically, Sanhuang Yilong Decoction has been shown to modulate the expression of aquaporins (AQPs) in the serum and synovial fluid, and to suppress inflammatory signaling pathways, including STAT and NF-kB, thereby downregulating pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and IL-17.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanhuang Yilong Decoction.